Integra LifeSciences sees 34% drop in Q2 revenue due to pandemic disruptions

On a preliminary basis, Integra LifeSciences (NASDAQ:IART) expects Q2 revenues of $254M – 256M, down ~34% from a year ago. On a more positive note, average daily sales in June were only down ~15% on the resumption of non-emergency surgical procedures and easing of shelter-in-place rules.

Management will update investors again during its Q2 earnings call on Monday, August 10, after the close.

https://seekingalpha.com/news/3590049-integra-lifesciences-sees-34-drop-in-q2-revenue-due-to-pandemic-disruptions